Please login to the form below

Not currently logged in
Email:
Password:

Authorised and branded generics set to rise by 2010

Many major pharma companies will enter the generics market by 2010 in an attempt to retain a competitive edge as their product patents run out, according to a study by market intelligence firm Cutting Edge Information.

Many major pharma companies will enter the generics market by 2010 in an attempt to retain a competitive edge as their product patents run out, according to a study by market intelligence firm Cutting Edge Information.

Pharma companies are battling with generics companies keen to step in when patents expire. One tactic is known as branded generics, where a company markets a generic version of its own brand in the hope that the brand and company association will give its generic version an edge over the competition.

Other companies are negotiating license-to-distribute agreements with generics manufacturers instead of competing with them directly. This is also expected to become a more common place practice in the future ­ the industry expects to see a 33 per cent increase in authorised generics by 2010.

In many cases, as with Pfizer's Greenstone, a company subsidiary springs up to fill the role of branded generics manufacturer.

According to Cutting Edge Information's study, Combating Generics 2008: Counter Generics Strategy, Planning and Execution, the industry expects a 75 per cent increase in generic subsidiaries between now and 2010.

"Both branded generics and authorised generics are becoming more common industry practices. In fact, half of the companies in our survey plan to employ one or both of these methods by the end of 2010," said research team leader Eric Bolesh.

Twenty-four pharma companies were profiled in the study, including Pfizer, AstraZeneca, GlaxoSmithKline, Novartis, sanofi-aventis and Roche.

14th February 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics